Short answer. FDA-approved labeling permits a dose increase in 2.5 mg steps after at least four weeks on the current dose, up to a maximum of 15 mg once weekly in adults. What labeling does not provide is a weight-based trigger. Mounjaro’s label ties escalation to glycemic control, because Mounjaro is approved for type 2 diabetes; using it for weight reduction alone is off-label. Zepbound, the tirzepatide product approved for weight management, instructs clinicians to “consider treatment response and tolerability” but defines neither term.
Key Takeaways
- Labeling permits 2.5 mg increases after a minimum of four weeks on the current dose — a minimum interval, not a schedule.
- The maximum labeled dose is 15 mg once weekly in adults for both tirzepatide products. For Mounjaro in patients aged 10 to 17, the maximum is 10 mg.
- Zepbound’s approved maintenance dosages are 5 mg, 10 mg and 15 mg. 7.5 mg and 12.5 mg are escalation steps, not maintenance dosages.
- No label names a weight-loss threshold that triggers a dose increase.
- A missed dose can be taken within four days (96 hours); two doses must not be taken within three days (72 hours) of each other.
- Both labels direct patients on oral hormonal contraceptives to use a non-oral or added barrier method for four weeks after each dose escalation.
When to Increase Mounjaro Dose for Weight Loss: What the Label Says
Two tirzepatide products exist, and their labels answer this question differently. Mounjaro’s escalation instruction is to increase in 2.5 mg increments after at least four weeks on the current dose, applied if additional glycemic control is needed — a glycemic trigger, not a weight-based one. Zepbound, which carries the weight indication, directs clinicians to consider treatment response and tolerability instead.
Mounjaro. Approved, as an adjunct to diet and exercise, to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. Its maximum dosage is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients.
Zepbound. Approved, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity, or in adults who are overweight in the presence of at least one weight-related comorbid condition. It is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. For the weight indication, its labeling specifies maintenance dosages of 5 mg, 10 mg or 15 mg and directs clinicians to consider treatment response and tolerability when selecting among them; for obstructive sleep apnea the maintenance dosage is 10 mg or 15 mg.
Both labels give the same reason for the gradual schedule itself: to reduce the risk of gastrointestinal adverse reactions. The interval exists to protect tolerability, not to pace weight loss.
| Key figure | What it means |
|---|---|
| 2.5 mg | Size of each labeled dose increase |
| 4 weeks | Minimum time at a dose before an increase is permitted |
| 15 mg | Maximum weekly dose in adults, both tirzepatide products |
| 96 hours | Window for taking a missed dose before it is skipped |
Why There Is No Weight-Based Rule to Look Up
People searching this question are usually looking for a threshold — a number of pounds, or a number of weeks without progress, that means it is time to move up. No published labeling provides one, and understanding why is more useful than working around it.
Mounjaro’s escalation criterion is glycemic: increase if additional glycemic control is needed. That criterion does not transfer to a patient using the drug for weight reduction, who may have normal blood sugar. Zepbound carries the weight indication, and its criterion is “treatment response and tolerability” — but the label does not define what adequate response looks like, over what period it should be assessed, or what degree of side effects counts as intolerance.
That is not an oversight. Response depends on starting weight, how much has already been lost, what the medication was prescribed for alongside weight, and what else is happening clinically. Those judgments belong to the clinician who knows the case, and this article does not supply a substitute.
Do not change your own dose. Dose selection and escalation are prescribing decisions. Do not increase, decrease, hold or restart a dose without the clinician who prescribed it, and do not use another person’s prescription or adjust a dose based on what worked for someone else.
The Mounjaro Dose Chart and Titration Schedule
The labeled titration schedule is the same for both tirzepatide products: start at 2.5 mg once weekly, then increase in 2.5 mg increments with a minimum of four weeks at each step, to a maximum of 15 mg once weekly in adults.
| Step | Weekly dose | Minimum before next increase | Status under the label |
|---|---|---|---|
| 1 | 2.5 mg | 4 weeks | Initiation only — not an approved Zepbound maintenance dosage |
| 2 | 5 mg | 4 weeks | Approved Zepbound maintenance dosage |
| 3 | 7.5 mg | 4 weeks | Escalation step |
| 4 | 10 mg | 4 weeks | Approved Zepbound maintenance dosage |
| 5 | 12.5 mg | 4 weeks | Escalation step |
| 6 | 15 mg | — | Approved Zepbound maintenance dosage; maximum in adults |
The Labeled Escalation Ladder
Bar width shows the dose relative to the 15 mg adult maximum; the week shown is the earliest the step can be reached
| 2.5 mg — initiation only | wk 1 | |
| 5 mg — maintenance dosage | wk 5 | |
| 7.5 mg — escalation step | wk 9 | |
| 10 mg — maintenance dosage | wk 13 | |
| 12.5 mg — escalation step | wk 17 | |
| 15 mg — adult maximum | wk 21 |
Figure 1. The labeled escalation schedule for both tirzepatide products. Four weeks is the minimum at each step, not a due date, so the weeks shown are the earliest possible rather than a schedule to expect. Source: FDA-approved prescribing information, Mounjaro revised 08/2026 and Zepbound revised 04/2026.
Two details in that table are easy to miss. The 2.5 mg dose exists for treatment initiation and is not approved as a maintenance dosage — it is there to let the body adjust, not to deliver the therapeutic effect. And for Zepbound, only 5 mg, 10 mg and 15 mg are approved maintenance dosages; 7.5 mg and 12.5 mg are marketed strengths that the label treats as steps on the way up, not places to settle.
Following the minimum interval at every step, the earliest anyone reaches 15 mg is around week 21, so the first five months are spent approaching the top of the schedule rather than sitting at it. Reaching the maximum is not an objective of treatment, and many patients do not.
A labeled instruction triggered by the dose increase itself. Both tirzepatide labels state that tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying, and advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method, for four weeks after starting treatment and for four weeks after each dose escalation. Hormonal contraceptives that are not taken orally are not expected to be affected. The labeling also states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that treatment be stopped when pregnancy is recognised.
How to Tell Whether Your Current Dose Is Working
Zepbound’s labeling directs clinicians to consider treatment response and tolerability, so what a patient observes between visits is part of the clinical picture rather than a side note. None of the following is a threshold for increasing a dose, and none should be acted on alone — they are what is worth recording and reporting.
Appetite and fullness. Reduced appetite between meals, feeling full earlier in a meal, and less preoccupation with food are the effects patients usually notice first, and they tend to appear before a change on the scale.
Rate and steadiness of weight change. What matters clinically is the direction and consistency over several weeks, not a single weigh-in. Weight moves for many reasons over a few days.
Tolerability at the current dose. A dose that is working but causing disruptive nausea, vomiting, diarrhea or constipation is a different situation from one that is working and comfortable, and it points toward a different decision.
What else has changed. Blood pressure, blood sugar if it is being monitored, sleep, energy and physical capacity are often the reason treatment was started. Progress there can matter as much as weight.
The useful thing to bring to an appointment is a short record: what changed, roughly when, and whether it is still changing. That is more informative than an impression formed on the day.
What Clinicians Weigh Before Increasing a Dose
In place of a threshold, these are the factors that inform the decision.
- Response so far, assessed over weeks rather than days, and against what was expected for that person rather than against a published average.
- Tolerability at the current dose. If nausea, vomiting, diarrhea or constipation are still disruptive four weeks in, that generally argues for holding rather than advancing, because symptoms commonly intensify after each increase before settling.
- Other medical factors. Kidney function, a history of pancreatitis or gallbladder disease, diabetic retinopathy, and concurrent insulin or sulfonylurea use all bear on whether and how fast to escalate. Because tirzepatide delays gastric emptying and thereby has the potential to affect the absorption of concomitantly administered oral medications, any oral medication where timing or blood level matters is also part of the review.
- Adherence and circumstances. Missed doses, supply interruptions, a change in eating pattern or an upcoming event that makes new side effects badly timed all legitimately affect the decision.
What to Report When Progress Stalls
A plateau is not automatically an indication to increase the dose, and treating it as one skips the questions a clinician asks first. Weight loss slows as it continues, and a slower rate at a higher dose is not the same thing as the medication failing.
Worth reviewing before any dose change:
- Adherence — how many doses have been taken on schedule, and whether any were missed or delayed.
- Eating pattern — protein intake and overall intake often drift once appetite is suppressed, in either direction.
- Activity — including whether resistance training is part of it, which bears on what is being lost.
- Sleep and stress, both of which affect appetite independently of medication.
- Other medications started or stopped since the last review.
- Hydration, particularly if gastrointestinal symptoms have been present.
If the plateau persists after those have been considered, that is a reason for a clinical review — not a reason to escalate on your own. The outcome of that review may be an increase, may be staying where you are, and may be something other than a dose change.
What the First Weeks After an Increase Look Like
Gastrointestinal symptoms commonly intensify after a dose increase. Labeling reports that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, and the trial literature describes these events as transient and of mild-to-moderate severity, but neither the labeling nor the published analyses give a specific duration.
What follows from that is practical rather than numeric. Symptoms in the days after an increase are not by themselves evidence that the dose is wrong. Symptoms that are still disruptive weeks later are a different signal, and one worth reporting rather than enduring.
Certain symptoms are not part of the adjustment pattern at any point and warrant contacting a clinician rather than waiting: severe abdominal pain, vomiting that prevents keeping fluids down, signs of dehydration, or reduced urine output.
What helps during the adjustment period. Smaller portions, eating more slowly, and keeping fluid intake up are the standard measures. If symptoms stop you eating or drinking normally, that is a reason to call your prescriber, not to push through.
What the Trial Data Says About Higher Doses
Higher doses did produce more weight reduction on average in the pivotal obesity trial, but the relationship is not linear and the gap narrows sharply at the top of the range.
In SURMOUNT-1, which enrolled 2,539 adults with obesity or overweight and without diabetes, mean weight reduction at week 72 was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% with placebo.
Mean Weight Change at Week 72 by Dose
SURMOUNT-1, adults without diabetes, n=2,539; discontinuation due to adverse events shown alongside
| 5 mg stopped for AEs 4.3% |
−15.0% | |
| 10 mg stopped for AEs 7.1% |
−19.5% | |
| 15 mg stopped for AEs 6.2% |
−20.9% | |
| Placebo stopped for AEs 2.6% |
−3.1% |
Figure 2. SURMOUNT-1, week 72, treatment-regimen estimand. Bar lengths are relative to the largest reduction shown. Group averages from one trial population, not predictions for any individual.
The step from 5 mg to 10 mg added 4.5 percentage points on average; the step from 10 mg to 15 mg added 1.4. Discontinuation due to adverse events was highest in the 10 mg arm rather than the 15 mg arm, so tolerability did not simply worsen with dose.
Two limits on reading those numbers. They are treatment-regimen estimands — group averages for a trial population, not predictions for an individual — and the trial studied tirzepatide for weight reduction in adults without diabetes, which is the Zepbound indication rather than Mounjaro’s.
Missed Doses, Holds and Stepping Back Down
Escalation rarely runs cleanly, and the labeling addresses the interruptions.
For a missed dose, the instruction is to take it as soon as possible within four days — 96 hours — of the scheduled day. If more than four days have passed, that dose is skipped and the next one is taken on the regular schedule; in either case the regular weekly schedule then resumes. The labeling also directs that two doses not be taken within three days (72 hours) of each other, so a missed dose is not made up by doubling.
Holding at a dose is a normal clinical decision, not a delay. The four-week interval is a minimum, and spending eight or twelve weeks at a step is unremarkable.
Stepping back down is anticipated rather than a setback. Zepbound’s labeling explicitly directs that a lower maintenance dosage be considered if the current one is not tolerated. Because its approved maintenance dosages are 5 mg, 10 mg and 15 mg — set out in our Zepbound dosage chart — a patient who reaches 10 mg and finds it difficult may be moved back to 5 mg rather than left at an escalation step such as 7.5 mg.
If treatment stops for an extended period, restarting at the previous dose may not be appropriate. The labeling does not address re-initiation after a long gap, so that is a judgment for the prescriber rather than a rule to look up.
One further caution about where medication comes from. Tirzepatide sold as “research-grade” or “not for human use”, or offered without a prescription, is illegally marketed. Compounded tirzepatide is a different category: it is not FDA approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. FDA has received multiple reports of adverse events, some requiring hospitalisation, that may be related to dosing errors with these products — a risk that compounds when someone is also adjusting their own dose. A vial is not itself a warning sign; the approved product is supplied in vials as well as pens, and the labeling instructs the use of an appropriate syringe.
For a fuller treatment of dosing safety and the boxed warning, see our guide to safe use of tirzepatide for weight loss. Side effects across the escalation period are covered in our complete guide to tirzepatide side effects, and what the weight-loss trajectory itself tends to look like is covered in Mounjaro weight loss by week. For the comparable semaglutide schedule, see our review of evidence-based semaglutide dosing.
Safety Information and When to Seek Care
Tirzepatide is a prescription medication carrying an FDA Boxed Warning for thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in patients with known serious hypersensitivity to tirzepatide or any of its excipients.
Other labeled risks include pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury, hypersensitivity reactions, hypoglycemia in combination with insulin or a sulfonylurea, pulmonary aspiration during general anesthesia or deep sedation, reduced efficacy of oral hormonal contraceptives, and gastrointestinal adverse reactions.
Seek medical attention for severe or persistent abdominal pain, vomiting that prevents keeping fluids down, signs of dehydration, reduced urine output, or symptoms of an allergic reaction. Tell any clinician planning a procedure requiring anesthesia or sedation that you are taking tirzepatide.
Talk to a Clinician About Your Dose
Whether it is time to increase your dose is answered by the clinician managing your treatment, with your history and current response in front of them.
Advanced TRT Clinic connects patients with independent licensed clinicians who can review where you are in the schedule, what you have observed, and what the next step should be — within their scope of practice and applicable state law. Availability varies by state, and services are provided to adults aged 18 and over only.